MSK physician shares kidney cancer research at annual ASCO GU Symposium

February 16, 2021

Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium held virtually February 11-13. Notably, MSK medical oncologist Robert Motzer, MD, presented encouraging data from a phase III randomized study that assessed two new treatment combinations as first-line treatments that may prolong survival in people with advanced kidney cancer. Dr. Motzer's findings were also published on February 13 in the New England Journal of Medicine.

In this large, international trial involving 200 sites across 20 countries, Dr. Motzer and a team of investigators evaluated two new regimens as first-line treatments for patients with advanced renal cell carcinoma (RCC) -- lenvatinib (Lenvima®) plus pembrolizumab (Keytruda®) and lenvatinib plus everolimus (Afinitor®) -- as compared with the current standard of care, sunitinib (Sutent®). They found that treatment with lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and a higher percentage of patients with an objective response versus sunitinib. Furthermore, results for overall survival were significantly longer in favor of lenvatinib plus pembrolizumab over sunitinib. Treatment with lenvatinib plus everolimus was also associated with a higher percentage of patients with an objective response and longer progression-free survival than sunitinib, but it did not have a significantly greater effect on overall survival.

"We are encouraged by all the data," said Dr. Motzer. "As physician-researchers, we consistently strive to provide our patients with the most effective therapies and give those with advanced disease more options. These results could lead to a change in the standard of care for these patients."

Dr. Motzer and colleagues concluded that lenvatinib plus pembrolizumab achieved significant improvements in progression-free survival, overall survival, and objective response rate versus sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.

Continuing to Make Strides in Research for Kidney Cancer Patients

Cancer immunotherapy was born at MSK a little over a century ago. Since then, physician-scientists across MSK have led the effort to develop immune-based treatments for different types of cancer. MSK has been at the epicenter of discoveries in the field, and the institution's work is bringing exciting new treatment options to people around the world. MSK physicians have extensive experience using immunotherapy to treat people with melanoma, kidney cancer, lung cancer, and other cancers, as well as in handling immune-related side effects.

Despite available therapies for advanced metastatic kidney cancer, new options are needed to improve long-term disease control and patient survival. Without treatment, kidney cancer can be an aggressive disease. At the time of diagnosis, the cancer has already spread to other organs in approximately 30 percent of people, and about one-third of people whose disease is confined to the kidney will have a relapse. In 2021, it is estimated that over 73,000 new cases of RCC will be diagnosed and there will be nearly 15,000 deaths due to RCC in the United States -- and numbers are expected to rise significantly in the next decade.

"Over the years we have made very encouraging progress in our overall understanding and treatment of advanced kidney cancer; however, ongoing research is very crucial so we can give patients better treatment options to help manage their disease," said Dr. Motzer.
-end-
This trial was sponsored by Eisai, Merck Sharp, and Dohme; CLEAR Clinical Trials.gov number NCT02811861.

About Memorial Sloan Kettering (MSK):

As the world's oldest and largest private cancer center, Memorial Sloan Kettering has devoted more than 135 years to exceptional patient care, influential educational programs and innovative research to discover more effective strategies to prevent, control and, ultimately, cure cancer. MSK is home to more than 20,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. Today, we are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science and technology supporting groundbreaking clinical studies, personalized treatment, and compassionate care for our patients. We also train the next generation of clinical and scientific leaders in oncology through our continually evolving educational programs, here and around the world. Year after year, we are ranked among the top two cancer hospitals in the country, consistently recognized for our expertise in adult and pediatric oncology specialties. http://www.mskcc.org.

Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.